As Ebola Outbreak Spreads in West Africa, U.S. Scientists Look for Cure

Just over a dozen American laboratories can experiment with the deadly virus, and one in Texas reports some promise in animal studies.

National Journal
Marina Koren
Add to Briefcase
Marina Koren
July 29, 2014, 11:15 a.m.

There’s a lot we don’t know about the Ebola vir­us.

The deadly vir­us likely comes from fruit bats, but sci­ent­ists don’t know for sure. They also don’t know all the ways the highly con­ta­gious vir­us is trans­mit­ted, nor how the dis­ease de­vel­ops with­in in­fec­ted people, al­most 90 per­cent of whom will die. And they don’t know to treat it or cure it.

Since Feb­ru­ary, the worst Ebola out­break West­ern Africa has ever seen has claimed more than 670 lives, in­clud­ing a prom­in­ent Liber­ia doc­tor who tried to con­tain the dis­ease. This month, the vir­us traveled by plane for the first time, when Patrick Saw­yer flew from Liber­ia to Ni­ger­ia, where he died days later from the vir­us.

As health work­ers try to con­tain the grow­ing out­break in Africa, sci­ent­ists 6,000 miles away are try­ing to de­vel­op the tools they need to do it.

Re­search­ers at the Galve­ston Na­tion­al Labor­at­ory in Texas are work­ing to pro­duce three prom­ising vac­cines and treat­ments for the Ebola vir­us, thanks to a $28 mil­lion grant from the Na­tion­al In­sti­tutes of Health. The labor­at­ory, op­er­ated by the Uni­versity of Texas Med­ic­al Branch, is one of only about 15 fa­cil­it­ies that are al­lowed to store and ex­per­i­ment with Ebola. The vir­us is clas­si­fied as a biosafety level 4 agent, the des­ig­na­tion giv­en by the Cen­ters for Dis­ease Con­trol and Pre­ven­tion to the most dan­ger­ous agents known to hu­mans. The Galve­ston labor­at­ory, and oth­er biosafety level 4 labs like it, is spe­cially equipped to handle — and con­tain — such agents.

The re­search­ers say they have had some suc­cess so far. “We have pre­vent­ive vac­cine and an­ti­vir­al drugs that can com­pletely pro­tect against Ebola on labor­at­ory an­im­als in a lab set­ting,” Thomas Geis­ber, a pro­fess­or of mi­cro­bi­o­logy and im­mun­o­logy at the Uni­versity of Texas Med­ic­al Branch, tells the loc­al ABC af­fil­i­ate. Geis­ber, like all re­search­ers and health work­ers who come in con­tact with the vir­us and in­fec­ted pa­tients, wears a pro­tect­ive body­suit every day while he works so he doesn’t con­tract Ebola him­self.

Ebola first ap­peared in 1976 in what is now known as the Demo­crat­ic Re­pub­lic of Congo. The vir­us at­tacks the im­mune sys­tem, caus­ing fever, vomit­ing, diarrhea and, in the most severe cases, in­tern­al and ex­tern­al bleed­ing. Ex­perts be­lieve the vir­us is trans­mit­ted through con­tact with in­fec­ted people’s bod­ily flu­ids. The most doc­tors can do is give pa­tients flu­ids, keep their blood pres­sure down, and hope for the best.

Like most re­search on the Ebola vir­us, the ex­per­i­ment­al treat­ments at Galve­ston have shown prom­ise only in an­im­als, and even those res­ults are far too pre­lim­in­ary. The Ebola vir­us is in­cred­ibly dif­fi­cult to study. It’s highly in­fec­tious, so it can only be stud­ied in high-tech fa­cil­it­ies like the one in Galve­ston, which means few­er re­search­ers are work­ing on de­vel­op­ing a cure. People in­fec­ted with the vir­us do not live long enough for doc­tors to ex­am­ine how the dis­ease pro­gresses, and giv­ing it to hu­man test sub­jects in the lab is not an op­tion.

Pre­vi­ous out­breaks have been con­trolled and even­tu­ally petered out, but this year’s is dif­fer­ent. Its rap­id growth, as well as Saw­yer’s death, have sparked fears that the vir­us could travel out­side of Africa, where the dis­ease has nev­er been re­por­ted in hu­mans. As NBC’s Mag­gie Fox put it, Ebola “is only a short plane ride from any city on Earth.”

What We're Following See More »
CITES CONFLICT OF INTEREST
Lieberman Withdraws from Consideration for FBI Job
3 days ago
THE LATEST
MINIMUM 2 PERCENT GDP
Trump Tells NATO Countries To Pay Up
4 days ago
BREAKING
MANAFORT AND FLYNN
Russians Discussed Influencing Trump Through Aides
4 days ago
THE DETAILS

"American spies collected information last summer revealing that senior Russian intelligence and political officials were discussing how to exert influence over Donald J. Trump through his advisers." The conversations centered around Paul Manafort, who was campaign chairman at the time, and Michael Flynn, former national security adviser and then a close campaign surrogate. Both men have been tied heavily with Russia and Flynn is currently at the center of the FBI investigation into possible collusion between the Trump campaign and Russia.

Source:
BUT WHITE HOUSE MAY USE AGAINST HIM ANYWAY
Ethics Cops Clear Mueller to Work on Trump Case
5 days ago
THE LATEST

"Former FBI Director Robert Mueller has been cleared by U.S. Department of Justice ethics experts to oversee an investigation into possible collusion between then-candidate Donald Trump's 2016 election campaign and Russia." Some had speculated that the White House would use "an ethics rule limiting government attorneys from investigating people their former law firm represented" to trip up Mueller's appointment. Jared Kushner is a client of Mueller's firm, WilmerHale. "Although Mueller has now been cleared by the Justice Department, the White House may still use his former law firm's connection to Manafort and Kushner to undermine the findings of his investigation, according to two sources close to the White House."

Source:
BUSINESSES CAN’T PLEAD FIFTH
Senate Intel to Subpoena Two of Flynn’s Businesses
5 days ago
THE LATEST

Senate Intelligence Committee chairman Richard Burr (R-NC) and ranking member Mark Warner (D-VA) will subpoena two businesses owned by former National Security Advisor Michael Flynn. Burr said, "We would like to hear from General Flynn. We'd like to see his documents. We'd like him to tell his story because he publicly said he had a story to tell."

×
×

Welcome to National Journal!

You are currently accessing National Journal from IP access. Please login to access this feature. If you have any questions, please contact your Dedicated Advisor.

Login